Med. Pro Praxi 2009; 6(5): 235-238

Immunoprophylaxis of recurrent herpes simplex infections

RNDr. Marek Petráš
Specialista v oboru vakcinologie, Praha

Recurrent herpes simplex infections are a persistent and distressing disease for which there has been no causal treatment. Currently,

immunoprophylaxis with Lupidon vaccines specific for type 1 or type 2 HSV is one of the many options available. Despite significant

improvement, immunoprophylaxis cannot be considered to be causal treatment that results in curing the patient.

Keywords: Lupidon, immunoprophylaxis, recurrent type 1 or type 2 herpes simplex infections, immunotherapy-induced cellular immunity.

Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petráš M. Immunoprophylaxis of recurrent herpes simplex infections. Med. praxi. 2009;6(5):235-238.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Scopp, Irwin Walter. Oral Medicine: A Clinical Approach with Basic Science Correlation 1969; 87-89.
    2. Darby ML, Bushee EJ. Mosby's: Comprehensive Review of Dental Hygiene. Second Edition 1991; 207-208, 258, 268-269.
    3. Avitabile E, Ward PL, Di Lazzaro C, Torrisi MR, Roizman B, Campadelli-Fiume G. The herpes simplex virus UL20 protein compensates for the differential disruption of exocytosis of virions and viral membrane glycoproteins associated with fragmentation of the Golgi apparatus. J Virol. 1994 68(11): 7397-7405. Go to original source... Go to PubMed...
    4. Hakama M, Louhivouri K. In: Herpes and Papilloma Viruses, Vol. II. De Palo G., Rilke F. Zur Hausen H. Serono Symposia Publications from Raven Press, New York, Vol. 46, 1986.
    5. Giovarelli M, Viano I, Zucca M, Valbonesi R, Dianzani F. Infect. Immun. 1977; 16(3): 849-852. Go to original source... Go to PubMed...
    6. Rapp F. University of Pennsylvania (USA). Reinbeker Kollokuium. Tel Aviv 1976.
    7. Petersen EE. Oncogenizität von Herpes simplex Viren und Lupidon. Haut Kr. 1977; 52(7): 417-426.
    8. Qadripur SA. Ergebnisse einer kontrollierten klinischen Studie mit dem Herpes-antigen Lupidon gegen Placebo. Aktuelle Dermatologie 1976; 3: 131-136.
    9. Weitgasser H. Kontrollierte klinische Studie mit den Herpes-Antigenen Lupidon H und Lupidon G. Boll. Ist. Sieroter. Milan. 1977; 66(6): 625-628.
    10. Koinis G, et al. Bericht uber eine Herpes-simplex-Vakzine (Lupidon H und G) fur die Behandlung des rezidivierenden Herpes simplex. Schweiz. Rundschau Med. Praxis 1975; 64(37): 1176-1179.
    11. Eichman A. Therapie von Herpes simplex Rezidivans. Z. Hautkr. 1977; 52(8): 475-482. Go to PubMed...
    12. Schmersahl P, et al. Behandlungsergebnisse mit dem Herpes simplex-antigen Lupidon H bzw. Lupidon G. Sonderdruck aus Zeitschrift fur Hautkrankheiten. 1975; 50(3): 105-111. Go to PubMed...
    13. Schneider J, et al. Zur Antigentherapie des Rezidivierenden Herpes simplex mit dem Herpes simplex-Impfstoff Lupidon H and G. Z. Hautkr. 1972; 47(24): 973-980.
    14. Mastrolorenzo A, et al. Multicentre clinical trial with Herpes simplex virus vaccine in recurrent herpes infection. Int. J. Std & AIDs. 1995; 6: 431-435. Go to original source... Go to PubMed...
    15. Altomare GF, et al. Recurrent Herpes simplex specific immuno-therapy with killed virus. Acta Toxicologica et Therapeutica, 1986; 7(3): 201-210.
    16. Bleidl D, et al. Herpes labialis and Herpes genitalis therapy by means of specific immune stimulation. Acta Toxicologica et Therapeutica, 1987; 8(1): 13-33.
    17. Veneroni G, et al. Specific immunostimulation in the therapy of recurrent Herpes simplex 1 or 2. Bollettino Istituto Sieroterapico Milanese, 1987; 66(1): 427-434.
    18. Cristofolini M, et al. Controlled clinical trial of the immunological therapy of recurrent Herpes simplex infections. Rassegna di Dermatologia e Sifilografia, 1987; 40: 13-22.
    19. Tiradritti L, et al. Clinical and immunological effect of an antiherpes vaccine in patients suffering from recurrent facial or genital Herpes: a preliminary study. Farmaci e Terapia, 1988; 5(3): 195-205.
    20. Lombardo N, et al. Clinical evaluation of anti-Herpes vaccine in relapsing Herps simplex infections. G. Ital. Dermatol. Venereol. 1993; 128: 57-62.
    21. Catanzaro C, et al. Valutazione dell'efficacia del vaccino antierpetico nelle infezioni recidivanti da Herpes Simplex Virus. Chron. Derm. 1995; V(3): 347.
    22. Calista D, et al. Prophylactic treatment of recurrent herpes infections with specific immunostimulation with Lupidon G/H. Italian Journal of Dermatology and Venerology, 1997; 132(1): 27-32.
    23. Pivetti-Pezzi P, et al. Herpes Simplex Virus vaccine in recurrent herpetic ocular infection. Cornea, 1999; 18(1): 47-51. Go to original source... Go to PubMed...
    24. Accorinti M, et al. Prevention of herpetic eye disease by specific immunotherapy with heat-inactivated HSV1. Boll. Ocul. Anno 1996; 75(1): 1996, 1-12.
    25. Battista MC, et al. Use of antiherpetic vaccine, derived from herpes simplex virus heat killed, in the prevention of recurrent eye infections from HSV. Boll. Ocul. Anno 1996; 75(1): 13-28.
    26. Ferrante M, et al. Clinical and immunological evaluation of the efficacy of an antiherpes simplex I vaccine therapy and hypothesis of management of relapsing herpetic keratitis. Boll. Ocul. Anno 1996; 75(1): 29-39.
    27. Martello C. Anti-herpes vaccine: personal experience on the treatment of keratouveitis by HSV1. Boll. Ocul. Anno 1996; 75(1): 41-49.
    28. Salvetat ML. Clinical use of heat-inactivated herpes simplex virus vaccine in the prophylaxis of herpetic dendritic and stromal recurrent keratitis. Boll. Ocul Anno 1996; 75(1): 51-74.
    29. Actis G. Further notes on the therapeutic results and immunological response of a heat-inactivated anti-herpes vaccine. Minerva Ophthalmologica. Aprile-Giugno 1977; 19(2): 48-80.
    30. De Maria A. Use of an antiherpetic vaccine in the HSV1 recurrent infections: preliminary results. Rivista di patologia clinica. 1993; XLVIII(2).

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.